ライフサイエンスコーパス: osmolar

1 METHODS: Single-dose pharmacokinetics of low-osmolar 1% maraviroc (MVC), 1% tenofovir (TFV), or 1% MV

2 Reactions to all available high-osmolar and four low-osmolar contrast media (ioxaglate,

3 mmercial lubricants were compounded into iso-osmolar and hyperosmolar mixtures (283 and 3429 mOsm/kg,

4 These two pathways specifically sense osmolar and pheromone signals, despite sharing a MAPKKK,

5 st agents can be divided into monomeric, low-osmolar, and dimeric, iso-osmolar classes.

6 tions, ranging from thermal, tactile, taste, osmolar, and fluid flow sensing to transepithelial Ca2+

7 molality, suggesting that these miRs mediate osmolar changes via AQP1.

8 nto monomeric, low-osmolar, and dimeric, iso-osmolar classes.

9 the escaped animals were also markedly hypo-osmolar compared to controls as a result of water loadin

10 similarly after treatment with NaCl, an equi-osmolar concentration of sorbitol, or ABA, whereas AtNHX

11 activity was robust in these cells in normal osmolar conditions and increased by approximately twofol

12 L. interrogans serovar Copenhageni adapts to osmolar conditions that correspond with invasion of a ma

13 the primary choline transporters under hypo-osmolar conditions whereas BetT3 was the major choline t

14 rons is markedly exacerbated by chronic hypo-osmolar conditions, but neuronal survival is not enhance

15 Low osmolar contrast agents appear to improve the safety of

16 a single biphasic injection of 130 mL of iso-osmolar contrast material (100 mL at 5 mL/sec and 30 mL

17 erwent intravenous administration of the iso-osmolar contrast material (IOCM) iodixanol 320 and patie

18 medication in patients receiving low- or iso-osmolar contrast material to prevent recurrent radiocont

19 approximately 3.6 times higher with all low-osmolar contrast media (2.3%) than with high-osmolar med

20 s to all available high-osmolar and four low-osmolar contrast media (ioxaglate, iohexol, iopamidol, a

21 ar contrast medium (IOCM) iodixanol with low-osmolar contrast media (LOCM) and to identify predictors

22 e versus IV saline in patients receiving low-osmolar contrast media (RR, 0.65 [CI, 0.33 to 1.25]; low

23 a slight reduction in CIN risk with the iso-osmolar contrast media agent iodixanol compared with a d

24 investigate the cardiovascular effect of iso-osmolar contrast media and the image quality achieved.

25 With high-osmolar contrast media compared with the three noncharge

26 g coronary angioplasty, the use of ionic low osmolar contrast media reduces the risk of ischemic comp

27 with data from 1980 to 1984, when only high-osmolar contrast media were available.

28 cification can be achieved with iso- and low-osmolar contrast media when it is injected at the same i

29 randomized to receive nonionic or ionic low osmolar contrast media.

30 at comparable iodine delivery rates, the iso-osmolar contrast medium iodixanol 270 is not inferior to

31 medium iodixanol 270 is not inferior to low-osmolar contrast medium iopromide 300 for assessment of

32 consent were obtained for the Effect of Iso-osmolar Contrast Medium on Coronary Opacification and He

33 Intravenous low-osmolar contrast-enhanced CT can safely be used in patie

34 myelinolysis who are subjected to aggressive osmolar correction may be rescued with appropriate fluid

35 and after intravenous administration of low-osmolar CT contrast.

36 h a tumor cell line was accomplished by hypo-osmolar electrofusion.

37 interrogans involves a transition from a low osmolar environment outside the host to a higher physiol

38 ent outside the host to a higher physiologic osmolar environment within the host.

39 no difference in renal sodium, potassium, or osmolar excretion, or in urine flow between groups.

40 ater transport and the mechanism of near iso-osmolar fluid reabsorption.

41 with the hyperosmolar gel than with the iso-osmolar formulation (median toxicity grade, 2.50 vs. 1.1

42 re determined by comparing serum lactate and osmolar gap at baseline, after 48 hrs, and at end of the

43 assium and bicarbonate levels, and anion and osmolar gap determination, as well as hepatic and renal

44 The clinical utility of the osmolar gap in preventing mannitol nephrotoxicity is emp

45 nce of a methanol concentration, the osmolal/osmolar gap may be informative; or, in the context of im

46 Neither serum lactate concentrations nor osmolar gap were significantly elevated over baseline.

47 ycol, can cause hyperlactatemia and elevated osmolar gaps.

48 oncentration at 10 cm, compared with the iso-osmolar gel (median, 8.9% vs. 54.6% of administered conc

49 al denudation and luminal secretion than iso-osmolar gels.

50 ivation of NSC currents in the absence of an osmolar gradient.

51 this receptor subtype is regulated by sodium/osmolar input.

52 cific toxic effect of monomeric nonionic low-osmolar iodinated contrast medium in ICU patients with m

53 dose in utero exposure to water-soluble, low-osmolar, iodinated intravenous products, such as iohexol

54 were prospectively randomized to receive iso-osmolar iodixanol 270 or low-osmolar iopromide 300 contr

55 onionic dimer iodixanol (n=405) with the low osmolar ionic agent ioxaglate (n=410).

56 Therefore, low osmolar ionic contrast media should be strongly consider

57 to receive iso-osmolar iodixanol 270 or low-osmolar iopromide 300 contrast media.

58 osure to 25 mmol/L d-glucose, but not to iso-osmolar mannitol, 1) reduced the ability of L-ASA to inh

59 for 60 min with 5-25 mmol/L d-glucose or iso-osmolar mannitol, we evaluated the influence of a 30-min

60 osmolar contrast media (2.3%) than with high-osmolar media (0.6%), usually in patients with pathologi

61 With high-osmolar media compared with ioxaglate, respectively, the

62 media compared with the three noncharged low-osmolar media, the incidence (per million examinations)

63 a, 19.0% with ioxaglate, and 10.4% with high-osmolar media.

64 corneal epithelial cells cultured in normal osmolar medium (312 mOsM) were exposed to media with hig

65 ury (PC-AKI) is low with the new low- or iso-osmolar non-ionic iodinated contrast agents.

66 , after use of iopamidol, a widely used, low osmolar, non-ionic, radiographic contrast medium.

67 ells were cultured in vitro with cycled hypo-osmolar or hyper-osmolar stresses, the AQY1 null yeast s

68 Three tenofovir rectal douches-220 mg iso-osmolar product A, 660 mg iso-osmolar product B, and 660

69 hes-220 mg iso-osmolar product A, 660 mg iso-osmolar product B, and 660 mg hypo-osmolar product C-wer

70 60 mg iso-osmolar product B, and 660 mg hypo-osmolar product C-were studied in 21 HIV-negative men wh

71 re deleterious to RPE (P < .001) even in iso-osmolar range.

72 to enhance their mechanical, functional and osmolar stability.

73 by aggressive correction of a hyper- or hypo-osmolar state and until recently has been associated wit

74 thy, symptomatic cerebral edema due to a low osmolar state, is a medical emergency and often encounte

75 milar mechanosensitivity in response to hypo-osmolar stress.

76 ironmental stresses including heat shock and osmolar stress.

77 d in vitro with cycled hypo-osmolar or hyper-osmolar stresses, the AQY1 null yeast showed significant

78 atient-level and hospital-level variation in osmolar therapy use and the substantial amount of sustai

79 use and the substantial amount of sustained osmolar therapy without intracranial pressure monitoring

80 Cl(-) reversal potential, particularly when osmolar transmembrane gradients are minimized, for examp